Colorectal cancer (CRC) is a major public health problem and a leading cause for human deaths in the world[@b1]. Although the pathogenesis of CRC remains largely unknown, a number of studies have demonstrated that CRC is a complex disease that results from environmental and genetic factors. Host genetic factors may play an important role in individual susceptibility to CRC[@b2][@b3].

MicroRNAs (miRNAs) are a class of endogenous, small, noncoding RNAs that modulate the activity of specific mRNA targets and play vital roles in a wide range of physiologic and pathologic processes. Increasing evidence showed that deregulation of miRNAs expression was involved in tumor initiation and progression. MiR-124 was initially confirmed to be a brain-enriched miRNA which was necessary for embryonic neuronal differentiation[@b4][@b5]. Recently, miR-124 has been found to be a potential tumor suppressor, which is epigenetically silenced in various types of cancer and regulates the biological behaviors of cancer cell by targeting several important genes, including rho-kinase 2 (ROCK2), enhancer of the zeste homologue 2 (EZH2), sphingosine kinase 1 (SPHK1) and the androgen receptor[@b6][@b7][@b8][@b9].

Single nucleotide polymorphisms (SNPs) are a type of common genetic variation associated with disease susceptibility[@b10]. The functional polymorphisms in the miRNA gene may affect the expression or function of miRNA, and have attracted increasing attention. A common polymorphism (rs531564, C \> G) in the pri-miR-124 has been identified and shown to influence the expression of mature miR-124[@b11]. In addition, pri-miR-124 rs531564 polymorphism was reported to be significantly correlated with the risk of various cancers, including cervical cancer and esophageal squamous cell carcinoma (ESCC)[@b12][@b13][@b14]. Thus, we hypothesized that the potentially functional polymorphism also contributed to the risk of CRC.

In the current study, we firstly conducted two independent case-control studies in Chinese population to investigate the associations, and then examined the clinicopathological characteristics of CRC for different genotypes.

Results
=======

Pri-miR-124 rs531564 polymorphism and CRC risk
----------------------------------------------

The selected characteristics of enrolled subjects are listed in [Table 1](#t1){ref-type="table"}. No significant difference was found in distributions of age and gender. Association of the pri-miR-124 rs531564 polymorphism with CRC risk was shown in [Table 2](#t2){ref-type="table"}. In Xuzhou population, the pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of CRC \[GG vs. CC: OR = 0.25, 95%CI = 0.09--0.67, *P* = 0.003; (CG+GG) vs. CC: OR = 0.73, 95%CI = 0.56--0.94, *P* = 0.01; GG vs. (CC+CG): OR = 0.27, 95%CI = 0.10--0.70, *P* = 0.004; G vs. C: OR = 0.70, 95%CI = 0.56--0.89, *P* = 0.003\]. Similar results were also observed in Bengbu population \[GG vs. CC: OR = 0.20, 95%CI = 0.04--0.90, *P* = 0.02; GG vs. (CC+CG): OR = 0.21, 95%CI = 0.05--0.95, *P* = 0.03; G vs. C: OR = 0.72, 95%CI = 0.54--0.98, *P* = 0.03\] and pooled population \[GG vs. CC: OR = 0.26, 95%CI = 0.11--0.59, *P *\< 0.001; (CG + GG) vs. CC: OR = 0.76, 95%CI = 0.62--0.93, *P* = 0.008; GG vs. (CC + CG): OR = 0.27, 95%CI = 0.12--0.62, *P *\< 0.001; G vs. C: OR = 0.71, 95%CI = 0.59--0.85, *P *\< 0.001\].

Clinicopathological characteristics of CRC for different genotypes
------------------------------------------------------------------

The association between pri-miR-124 rs531564 polymorphism and clinicopathological characteristic of CRC patients was conducted in two independent studies ([Table 3](#t3){ref-type="table"}). Significant associations were found in status of differentiation and lymph node metastasis. In CRC patients from Xuzhou city, the pri-miR-124 rs531564 polymorphism was associated with the decreased risk of poor differentiation \[(CG+GG) vs. CC: OR = 0.67, 95%CI = 0.45--0.99, *P* = 0.05; G vs. C: OR = 0.69, 95%CI = 0.48--0.99, *P* = 0.04\], and lymph node metastasis \[CG vs. CC: OR = 0.65, 95%CI = 0.43--0.96, *P* = 0.03; (CG+GG) vs. CC: OR = 0.64, 95%CI = 0.43--0.95, *P* = 0.03; G vs. C: OR = 0.67, 95%CI = 0.47--0.96, *P* = 0.03\]. In CRC patients from Bengbu city, the pri-miR-124 rs531564 polymorphism was also associated with the decreased risk of poor differentiation \[(CG + GG) vs. CC: OR = 0.56, 95%CI = 0.33--0.98, *P* = 0.04; G vs. C: OR = 0.58, 95%CI = 0.34--0.96, *P* = 0.03\], and lymph node metastasis \[(CG+GG) vs. CC: OR = 0.58, 95%CI = 0.34--0.97, *P* = 0.04; G vs. C: OR = 0.59, 95%CI = 0.37--0.96, *P* = 0.03\]. Furthermore, these associations of pri-miR-124 rs531564 polymorphism with the decreased risk of poor differentiation \[(CG+GG) vs. CC: OR = 0.66, 95%CI = 0.48--0.90, *P* = 0.01; G vs. C: OR = 0.65, 95%CI = 0.48--0.87, *P* = 0.003\] and lymph node metastasis \[CG vs. CC: OR = 0.71, 95%CI = 0.51--0.98, *P* = 0.04; (CG + GG) vs. CC: OR = 0.64, 95%CI = 0.47--0.88, *P* = 0.006; G vs. C: OR = 0.62, 95%CI = 0.46--0.82, *P *\< 0.001\] were also observed in pooled patients.

Discussion
==========

Similar to the protein-coding genes, miRNAs are transcribed for the majority by RNA polymerase II as long primary miRNA (pri-miRNAs) transcripts with stem-loop structure[@b15]. The pri-miRNAs are processed to produce miRNA precursors (pre-miRNAs) and then further cleaved into mature miRNAs which act mainly through annealing to 3′ untranslated regions (3′UTRs) of gene transcripts, leading to inhibition of further steps of gene expression. MiR-124 is a highly conserved miRNA and plays an important role in neural processes, from nervous system development to normal neuronal cell function[@b16]. Nowadays, miR-124 has been reported to be a potential tumor suppressor and an independent prognostic marker in many cancers, including colorectal cancer, prostate cancer, and nasopharyngeal carcinoma[@b17][@b18][@b19]. The miR-124 gene is located in 8p23 and has an identified polymorphism (rs531564) which affects miR-124 expression[@b11]. The associations of rs531564 polymorphism and cancer risk have been reported; however, the results of previous studies are controversial. Most studies showed that rs531564 polymorphism was associated with decreased risk of cancer, such as cervical cancer and esophageal squamous cell carcinoma; however, one study indicated no association between rs531564 polymorphism and cancer risk including esophageal cancer, which was probably due to difference in genotyping method, cancer type or source of controls[@b12][@b13][@b14][@b20].

In two independent case-control studies from Xuzhou population (577 CRC patients and 690 healthy controls) and Bengbu population (323 CRC cases and 420 healthy subjects), we found that pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of CRC, which is similar to the results of the recent meta-analysis[@b21]. Analysis based on bioinformatics and gene expression showed that the G allele in the rs531564 polymorphism changed the formation of a ring-shaped structure in miR-124, which was beneficial to the increase of the amount of mature miR-124[@b11]. Therefore, we speculated that the role of pri-miR-124 rs531564 polymorphism in CRC susceptibility was associated with the stability of the pri-miRNA, or the efficiency of processing of pri-miRNA into mature miRNA. Furthermore, our results showed that pri-miR-124 rs531564 polymorphism was significantly associated with clinicopathological characteristics of CRC patients, including poor differentiation and lymph node metastasis. To the best of our knowledge, this is the first molecular epidemiological study to investigate the associations of pri-miR-124 rs531564 polymorphism with the risk and clinicopathological characteristics of CRC. However, we could not determine the interaction between pri-miR-124 rs531564 polymorphism and potential risk factors, such as drinking, red meat consumption and body mass index, because of a lack of enough individual data in case-control studies.

Taken together, our findings suggest that pri-miR-124 rs531564 polymorphism contributes to the decreased risk of CRC, poor differentiation and lymph node metastasis in Chinese population, possibly by affecting miR-124 expression. However, further research in this field is warranted to complete understanding of carcinogenesis associated with the pri-miR-124 rs531564 polymorphism.

Materials and Methods
=====================

Study population
----------------

Two independent case-control studies were conducted in unrelated ethnic Han Chinese. Briefly, 577 CRC patients and 690 age and gender frequency-matched healthy controls were recruited from the Affiliated Hospital of Xuzhou Medical College between July 2013 and December 2014, and 323 CRC cases and 420 cancer-free controls were enrolled from December 2013 to January 2015 in the Affiliated Hospital of Bengbu Medical College. Patients were confirmed by routine histopathological examination and received no chemotherapy or radiation therapy before surgery. Control subjects were without any previous cancer diagnosis and selected from a pool of controls by normal physical examination. Demographic and clinicopathological data were collected from medical records and histopathology reports. Written informed consent was obtained from all patients and healthy control subjects before study entry. The study design and protocol were approved by the ethics committee of The Affiliated Hospital of Bengbu Medical College and Xuzhou Medical College, China. Methods were carried out in accordance with the approved guidelines.

DNA extraction and genotyping
-----------------------------

The genomic DNA of each subject was isolated from peripheral blood samples using genomic DNA extraction kit (Qiagen) according to the manufacturer's protocol. DNA fragments containing rs531564 were amplified with the following primers (forward: 5-TCTTCTACCCACCCCTCTTCC-3; reverse: 5-AATCTGCACACACAAGCACTC-3). The PCR products were sequenced in forward direction. The SNP genotypes were determined by DNAMAN and BLAST.

Statistical Analysis
--------------------

Differences in general characteristics were examined using Student's *t*-test or χ^2^ test. The Hardy-Weinberg equilibrium (HWE) was tested by a goodness-of-fit χ^2^ test to compare the expected genotype frequencies with observed genotype frequencies in cancer-free controls. Logistic regression was used to analyze the association between the rs531564 polymorphism and the risk and clinicopathological characteristics of CRC, adjusted by confounding factors including age, gender, family history of cancer, tumor site, differentiation, TNM and/or lymph node metastasis when appropriate. In [Table 3](#t3){ref-type="table"}, all the comparisons are done using the second characteristic as reference. *P *\< 0.05 was used as the criterion of statistical significance. All statistical analyses were implemented in the SPSS statistical software (version 19.0).
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###### General characteristics of study population.

  **Characteristics**         **Xuzhou population**   **Bengbu population**   **Pooled population**                            
  -------------------------- ----------------------- ----------------------- ----------------------- ------------ ------------ -------------
  Age                                                                                                                          
  ≤60 years                        277 (48.0)              334 (48.4)              174 (53.9)         235 (56.0)   451 (50.1)   569 (51.3)
  \>60 years                       300 (52.0)              356 (51.6)              149 (46.1)         185 (44.0)   449 (49.9)   541 (48.7)
  Gender                                                                                                                       
  Male                             325 (56.3)              399 (57.8)              187 (57.9)         226 (53.8)   512 (56.9)   625 (56.3)
  Female                           252 (43.7)              291 (42.2)              136 (42.1)         194 (46.2)   388 (43.1)   485 (43.7)
  Family history of cancer                                                                                                     
  Yes                               71 (12.3)               63 (9.1)                33 (10.2)          34 (8.1)    104 (11.6)    97 (8.7)
  No                               506 (87.7)              627 (90.9)              290 (89.8)         386 (91.9)   796 (88.4)   1013 (91.3)
  Tumor site                                                                                                                   
  Rectum                           311 (53.9)                                      180 (55.7)                      491 (54.6)         
  Colon                            266 (46.1)                                      143 (44.3)                      409 (45.4)         
  Differentiation                                                                                                              
  Poor                             289 (50.1)                                      131 (40.6)                      420 (46.7)         
  Good + Moderate                  288 (49.9)                                      192 (59.4)                      480 (53.3)         
  Lymph node metastasis                                                                                                        
  Yes                              301 (52.2)                                      165 (51.1)                      466 (51.8)         
  No                               276 (47.8)                                      158 (48.9)                      434 (48.2)         
  TNM pathological stage                                                                                                       
  I and II                         248 (43.0)                                      152 (47.1)                      400 (44.4)         
  III and IV                       329 (57.0)                                      171 (52.9)                      500 (55.6)         

###### The genotype and allele frequencies of the pri-miR-124 rs531564 polymorphism in CRC patients and controls

  **Model comparison**    **Genotype/allele**   **Cases, n (%)**      **Controls, n (%)**      **OR (95% CI)**   ***P*-value**
  ---------------------- --------------------- ------------------ --------------------------- ----------------- ---------------
  Co-dominant model        Xuzhou population        n = 577                 n = 690                                     
  CC                          446 (77.3)           492 (71.3)              Reference                            
  CG                          126 (21.8)           176 (25.5)          0.79 (0.61--1.02)            0.07        
  GG                            5 (0.9)             22 (3.2)       **0.25 (0.09**--**0.67)**      **0.003**     
  Dominant model                  CC               446 (77.3)             492 (71.3)              Reference             
  CG+GG                       131 (22.7)           198 (28.7)      **0.73 (0.56**--**0.94)**      **0.01**      
  Recessive model                CC+CG             572 (99.1)             668 (96.8)              Reference             
  GG                            5 (0.9)             22 (3.2)       **0.27 (0.10**--**0.70)**      **0.004**     
  Allele model                     C              1018 (88.2)             1160 (84.1)             Reference             
  G                           136 (11.8)           220 (15.9)      **0.70 (0.56**--**0.89)**      **0.003**     
  Bengbu population             n = 323             n = 420                                                     
  Co-dominant model               CC               247 (76.5)             298 (71.0)              Reference             
  CG                           74 (22.9)           110 (26.2)          0.81 (0.58--1.14)            0.22        
  GG                            2 (0.6)             12 (2.9)       **0.20 (0.04**--**0.90)**      **0.02**      
  Dominant model                  CC               247 (76.5)             298 (71.0)              Reference             
  CG+GG                        76 (23.5)           122 (29.0)          0.75 (0.54--1.04)            0.09        
  Recessive model                CC+CG             321 (99.4)             408 (97.1)              Reference             
  GG                            2 (0.6)             12 (2.9)       **0.21 (0.05**--**0.95)**      **0.03**      
  Allele model                     C               568 (87.9)             706 (84.0)              Reference             
  G                            78 (12.1)           134 (16.0)      **0.72 (0.54**--**0.98)**      **0.03**      
  Pooled population             n = 900             n = 1110                                                    
  Co-dominant model               CC               693 (77.0)             790 (71.2)              Reference             
  CG                          200 (22.2)           286 (25.8)          0.81 (0.66--1.00)            0.05        
  GG                            7 (0.8)             34 (3.1)       **0.26 (0.11**--**0.59)**     **\<0.001**    
  Dominant model                  CC               693 (77.0)             790 (71.2)              Reference             
  CG+GG                       207 (23.0)           320 (28.8)      **0.76 (0.62**--**0.93)**      **0.008**     
  Recessive model                CC+CG             893 (99.2)             1076 (96.9)             Reference             
  GG                            7 (0.8)             34 (3.1)       **0.27 (0.12**--**0.62)**     **\<0.001**    
  Allele model                     C              1586 (88.1)             1866 (84.1)             Reference             
  G                           214 (11.9)           354 (15.9)      **0.71 (0.59**--**0.85)**     **\<0.001**    

###### Association between pri-miR-124 rs531564 polymorphism and clinicopathological characteristic of CRC patients

                              **Cases**   **CG versus CC**   **(CG+GG) versus CC**        **G versus C**                                                                                       
  -------------------------- ----------- ------------------ ----------------------- --------------------------- ---------- --------------------------- ----------- --------------------------- -------------
  Xuzhou                                                                                                                                                                                       
  Age                                                                                                                                                                                          
  ≤60 years                      214             60                    3                 0.98 (0.66--1.45)         0.91         1.00 (0.67--1.47)         0.98          1.02 (0.72--1.46)          0.90
  \>60 years                     232             66                    2                                                                                                                              
  Gender                                                                                                                                                                                       
  Male                           250             72                    3                 1.03 (0.69--1.54)         0.87         1.04 (0.70--1.54)         0.85          1.05 (0.73--1.51)          0.80
  Female                         196             54                    2                                                                                                                              
  Family history of cancer                                                                                                                                                                     
  Yes                            56              15                    0                 0.94 (0.51--1.72)         0.83         0.88 (0.48--1.61)         0.67          0.87 (0.49--1.53)          0.63
  No                             390            111                    5                                                                                                                              
  Tumor site                                                                                                                                                                                   
  Rectum                         240             67                    4                 0.97 (0.65--1.44)         0.86         1.01 (0.68--1.49)         0.98          1.06 (0.74--1.52)          0.76
  Colon                          206             59                    1                                                                                                                              
  Differentiation                                                                                                                                                                              
  Poor                           233             55                    1                 0.70 (0.47--1.05)         0.08     **0.67 (0.45**--**0.99)**   **0.05**    **0.69 (0.48**--**0.99)**    **0.04**
  Good + Moderate                213             71                    4                                                                                                                              
  Lymph node metastasis                                                                                                                                                                        
  Yes                            244             55                    2             **0.65 (0.43**--**0.96)**   **0.03**   **0.64 (0.43**--**0.95)**   **0.03**    **0.67 (0.47**--**0.96)**    **0.03**
  No                             202             71                    3                                                                                                                              
  TNM pathological stage                                                                                                                                                                       
  I and II                       195             50                    3                 0.84 (0.56--1.26)         0.41         0.87 (0.59--1.29)         0.49          0.92 (0.64--1.32)          0.65
  III and IV                     251             76                    2                                                                                                                              
  Bengbu                                                                                                                                                                                       
  Age                                                                                                                                                                                          
  ≤60 years                      131             42                    1                 1.14 (0.68--1.93)         0.62         1.13 (0.68--1.90)         0.63          1.12 (0.70--1.81)          0.63
  \>60 years                     116             32                    1                                                                                                                              
  Gender                                                                                                                                                                                       
  Male                           145             41                    1                 0.87 (0.51--1.46)         0.59         0.86 (0.51--1.45)         0.57          0.88 (0.55--1.42)          0.60
  Female                         102             33                    1                                                                                                                              
  Family history of cancer                                                                                                                                                                     
  Yes                            24              9                     0                 1.28 (0.56--2.88)         0.56         1.24 (0.55--2.79)         0.61          1.17 (0.55--2.47)          0.68
  No                             223             65                    2                                                                                                                              
  Tumor site                                                                                                                                                                                   
  Rectum                         132             46                    2                 1.41 (0.83--2.40)         0.21         1.47 (0.86--2.49)         0.15          1.49 (0.91--2.43)          0.11
  Colon                          115             28                    0                                                                                                                              
  Differentiation                                                                                                                                                                              
  Poor                           108             23                    0                 0.59 (0.34--1.02)         0.06     **0.56 (0.33**--**0.98)**   **0.04**    **0.58 (0.34**--**0.96)**    **0.03**
  Good + Moderate                139             51                    2                                                                                                                              
  Lymph node metastasis                                                                                                                                                                        
  Yes                            134             31                    0                 0.60 (0.36--1.02)         0.06     **0.58 (0.34**--**0.97)**   **0.04**    **0.59 (0.37**--**0.96)**    **0.03**
  No                             113             43                    2                                                                                                                              
  TNM pathological stage                                                                                                                                                                       
  I and II                       110             40                    2                 1.45 (0.86--2.45)         0.16         1.53 (0.91--2.56)         0.11          1.53 (0.95--2.47)          0.08
  III and IV                     137             34                    0                                                                                                                              
  Xuzhou and Bengbu                                                                                                                                                                            
  Age                                                                                                                                                                                          
  ≤60 years                      345            102                    4                 1.05 (0.76--1.43)         0.78         1.06 (0.77--1.44)         0.73          1.06 (0.80--1.41)          0.69
  \>60 years                     348             98                    3                                                                                                                              
  Gender                                                                                                                                                                                       
  Male                           395            113                    4                 0.97 (0.71--1.34)         0.87         0.97 (0.71--1.33)         0.85          0.98 (0.74--1.31)          0.91
  Female                         298             87                    3                                                                                                                              
  Family history of cancer                                                                                                                                                                     
  Yes                            80              24                    0                 1.04 (0.64--1.69)         0.87         1.02 (0.63--1.65)         0.95          0.96 (0.61--1.51)          0.87
  No                             613            176                    7                                                                                                                              
  Tumor site                                                                                                                                                                                   
  Rectum                         372            113                    6                 1.12 (0.81--1.53)         0.49         1.16 (0.85--1.59)         0.34          1.19 (0.89--1.60)          0.23
  Colon                          321             87                    1                                                                                                                              
  Differentiation                                                                                                                                                                              
  Poor                           341             78                    1                 0.73 (0.52--1.00)         0.05     **0.66 (0.48**--**0.90)**   **0.01**    **0.65 (0.48**--**0.87)**    **0.003**
  Good + Moderate                352            122                    6                                                                                                                              
  Lymph node metastasis                                                                                                                                                                        
  Yes                            378             86                    2             **0.71 (0.51**--**0.98)**   **0.04**   **0.64 (0.47**--**0.88)**   **0.006**   **0.62 (0.46**--**0.82)**   **\<0.001**
  No                             315            114                    5                                                                                                                              
  TNM pathological stage                                                                                                                                                                       
  I and II                       305             90                    5                 1.04 (0.75--1.42)         0.83         1.07 (0.79--1.47)         0.66          1.11 (0.83--1.48)          0.47
  III and IV                     388            110                    2                                                                                                                              
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